HAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a Tertiary Care Center in Sao Paulo, Brazil

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Edvaldo F. da
dc.contributor.authorMAZO, Daniel F.
dc.contributor.authorOLIVEIRA, Claudia P.
dc.contributor.authorMEDEIROS, Roseane P.
dc.contributor.authorCARRILHO, Flair J.
dc.contributor.authorPESSOA, Mario G.
dc.date.accessioned2017-06-09T15:33:25Z
dc.date.available2017-06-09T15:33:25Z
dc.date.issued2016
dc.description.abstractBackground. Patients with chronic HCV infection and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV infection. Therefore, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Material and methods: One thousand chronic HCV patients at the University of Sao Paulo School of Medicine were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 92.3% of patients. When stratified by age, anti-HAV IgG was found in 61% of patients between 20-29 years, 70% on patients between 30-39 years, 85% on patients between 40-49 years, 94% on patients between 50-59 years, and in 99% on patients over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, in 4.3% of patients between 20-29 years, 17% 30-39 years, 21% 40-49 years, 24% 50-59 years, and in 28% of patients over 60 years. Of the 244 anti-HBc IgG positive patients, 0.8% were HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: In conclusion, the prevalence of anti-HAV IgG was similar to the general Brazilian population. However, anti-HBc IgG was higher in our patients, when compared to general population of Western countries, emphasizing the importance of immunization programs for this population.
dc.description.indexMEDLINE
dc.description.sponsorshipCAPES (Coordenagao de Aperfeicoamento de Pessoal de Nivel Superior)
dc.identifier.citationANNALS OF HEPATOLOGY, v.15, n.5, p.691-695, 2016
dc.identifier.doi10.5604/16652681.1212320
dc.identifier.issn1665-2681
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/20047
dc.language.isoeng
dc.publisherMEXICAN ASSOC HEPATOLOGY
dc.relation.ispartofAnnals of Hepatology
dc.rightsrestrictedAccess
dc.rights.holderCopyright MEXICAN ASSOC HEPATOLOGY
dc.subjectChronic Hepatitis C
dc.subjectHepaclvirus
dc.subjectHepatitis A
dc.subjectHepatitis B
dc.subjectPrevalence
dc.subject.otherchronic hepatitis-c
dc.subject.otherchronic liver-disease
dc.subject.otherb-virus-infection
dc.subject.othera virus
dc.subject.othervaccination
dc.subject.otherprevalence
dc.subject.othersuperinfection
dc.subject.wosGastroenterology & Hepatology
dc.titleHAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a Tertiary Care Center in Sao Paulo, Brazil
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus4
hcfmusp.contributor.author-fmusphcEDVALDO FERREIRA DA SILVA
hcfmusp.contributor.author-fmusphcDANIEL FERRAZ DE CAMPOS MAZO
hcfmusp.contributor.author-fmusphcCLAUDIA PINTO MARQUES SOUZA DE OLIVEIRA
hcfmusp.contributor.author-fmusphcROSEANE PORTO MEDEIROS
hcfmusp.contributor.author-fmusphcFLAIR JOSE CARRILHO
hcfmusp.contributor.author-fmusphcMARIO GUIMARAES PESSOA
hcfmusp.description.beginpage691
hcfmusp.description.endpage695
hcfmusp.description.issue5
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.pubmed27493107
hcfmusp.origem.scopus2-s2.0-84982943422
hcfmusp.origem.wosWOS:000397061200004
hcfmusp.publisher.cityMEXICO
hcfmusp.publisher.countryMEXICO
hcfmusp.relation.referenceALBERTI A, 1995, J HEPATOL, V22, P38
hcfmusp.relation.referenceBuxton JA, 2008, CAN J INFECT DIS MED, V19, P197
hcfmusp.relation.referenceChen SL, INT J MED HEPATITI A
hcfmusp.relation.referenceCho HC, 2011, WORLD J GASTROENTERO, V17, P236, DOI 10.3748/wjg.v17.i2.236
hcfmusp.relation.referenceXimenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003
hcfmusp.relation.referenceDevalle S, 2003, J INFECTION, V47, P125, DOI 10.1016/S0163-4453(03)00061-6
hcfmusp.relation.referenceRedondo MPD, 2009, REV ESP ENFERM DIG, V101, P265
hcfmusp.relation.referenceFelsen UR, 2010, J ADDICT DIS, V29, P461, DOI 10.1080/10550887.2010.509281
hcfmusp.relation.referenceFocaccia R, 1998, BRAZ J INFECT DIS, V2, P269
hcfmusp.relation.referenceGiannini E, 2003, LIVER INT, V23, P12, DOI 10.1034/j.1600-0676.2003.01742.x
hcfmusp.relation.referenceIdilman R, 2002, AM J GASTROENTEROL, V97, P435
hcfmusp.relation.referenceKeeffe EB, 2005, AM J MED, V118, P21, DOI 10.1016/j.amjmed.2005.07.013
hcfmusp.relation.referenceKeeffe Emmet B, 2006, Trans Am Clin Climatol Assoc, V117, P227
hcfmusp.relation.referenceKim MN, 2013, J GASTROENTEROL, V48, P681, DOI 10.1007/s00535-013-0770-9
hcfmusp.relation.referenceKoff RS, 2001, J CLIN GASTROENTEROL, V33, P20, DOI 10.1097/00004836-200107000-00006
hcfmusp.relation.referenceKramer ES, 2009, DIGEST DIS SCI, V54, P2016, DOI 10.1007/s10620-009-0867-4
hcfmusp.relation.referenceLau DTY, 2005, AM J MED, V118, P28, DOI 10.1016/j.amjmed.2005.07.014
hcfmusp.relation.referenceLiaw YF, 2002, J GASTROENTEROL, V37, P65, DOI 10.1007/BF02990102
hcfmusp.relation.referenceLiu CJ, 2014, WORLD J GASTROENTERO, V20, P2955, DOI 10.3748/wjg.v20.i11.2955
hcfmusp.relation.referenceLiu Zhihua, 2006, Int J Med Sci, V3, P57
hcfmusp.relation.referenceMattos Angelo Alves de, 2004, Arq Gastroenterol, V41, P180
hcfmusp.relation.referenceMenegol D, 2013, BRAZ J MICROBIOL, V44, P1237, DOI 10.1590/S1517-83822014005000013
hcfmusp.relation.reference[Departamento de Vigiiiancia Epidemiologica Brazil. Ministry of Health], 2014, INF TECN INTR VAC AD
hcfmusp.relation.referenceReiss G, 2004, ALIMENT PHARM THERAP, V19, P715, DOI 10.1111/j.1365-2036.2004.01906.x
hcfmusp.relation.referenceRowe IA, 2012, HEPATOLOGY, V56, P501, DOI 10.1002/hep.25683
hcfmusp.relation.referenceSaab S, 2005, J VIRAL HEPATITIS, V12, P101, DOI 10.1111/j.1365-2893.2005.00551.x
hcfmusp.relation.referenceSemnani S, 2006, PAKISTAN J BIOL SCI, V9, P2538
hcfmusp.relation.referenceShim M, 2005, HEPATOLOGY, V42, P688, DOI 10.1002/hep.20830
hcfmusp.relation.referenceSiddiqui F, 2001, AM J GASTROENTEROL, V96, P858
hcfmusp.relation.referenceTao YL, 2013, WORLD J GASTROENTERO, V19, P5320, DOI 10.3748/wjg.v19.i32.5320
hcfmusp.relation.referenceTaye Solomon, 2014, BMC Res Notes, V7, P272, DOI 10.1186/1756-0500-7-272
hcfmusp.relation.referenceVento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503
hcfmusp.relation.referenceVillar LM, 2009, J GASTROEN HEPATOL, V24, P238, DOI 10.1111/j.1440-1746.2008.05575.x
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationa52615ff-f723-4c92-8821-a2c627f6d032
relation.isAuthorOfPublication1e94e0c4-f090-4c70-9f0c-9212a178d7be
relation.isAuthorOfPublication6fe5bca4-b5ef-47da-b77a-5e60d87e165f
relation.isAuthorOfPublicationcc0014d2-86af-45b3-8962-f6f6d5283455
relation.isAuthorOfPublication9221b8d6-ad80-46e5-a56f-fb3b28a8c155
relation.isAuthorOfPublication0baf66bd-afb9-4844-b40c-485b3c558f66
relation.isAuthorOfPublication.latestForDiscoverya52615ff-f723-4c92-8821-a2c627f6d032
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SILVA_HAV_and_HBV_seroprevalence_in_1000_patients_with_2016.PDF
Tamanho:
133.74 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03